These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25625510)

  • 1. Comparing WTP values of different types of QALY gain elicited from the general public.
    Pennington M; Baker R; Brouwer W; Mason H; Hansen DG; Robinson A; Donaldson C;
    Health Econ; 2015 Mar; 24(3):280-93. PubMed ID: 25625510
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of willingness to pay per quality-adjusted life year for a cure: A contingent valuation method using a scenario-based survey.
    Song HJ; Lee EK
    Medicine (Baltimore); 2018 Sep; 97(38):e12453. PubMed ID: 30235732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.
    Lieu TA; Ray GT; Ortega-Sanchez IR; Kleinman K; Rusinak D; Prosser LA
    Pharmacoeconomics; 2009; 27(12):1005-16. PubMed ID: 19908925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How you ask is what you get: Framing effects in willingness-to-pay for a QALY.
    Ahlert M; Breyer F; Schwettmann L
    Soc Sci Med; 2016 Feb; 150():40-8. PubMed ID: 26730880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Contingent Valuation Study for Eliciting a Monetary Value of a Quality-Adjusted Life-Year in the General Greek Population.
    Mavrodi A; Aletras V
    Value Health Reg Issues; 2020 Sep; 22():36-43. PubMed ID: 32731168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimating a WTP-based value of a QALY: the 'chained' approach.
    Robinson A; Gyrd-Hansen D; Bacon P; Baker R; Pennington M; Donaldson C;
    Soc Sci Med; 2013 Sep; 92():92-104. PubMed ID: 23849283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.
    Olofsson S; Norrlid H; Persson U
    J Med Econ; 2016 Oct; 19(10):945-58. PubMed ID: 27149402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of a QALY: individual willingness to pay for health gains under risk.
    Bobinac A; van Exel J; Rutten FF; Brouwer WB
    Pharmacoeconomics; 2014 Jan; 32(1):75-86. PubMed ID: 24293198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Weighting and valuing quality-adjusted life-years using stated preference methods: preliminary results from the Social Value of a QALY Project.
    Baker R; Bateman I; Donaldson C; Jones-Lee M; Lancsar E; Loomes G; Mason H; Odejar M; Pinto Prades JL; Robinson A; Ryan M; Shackley P; Smith R; Sugden R; Wildman J;
    Health Technol Assess; 2010 May; 14(27):1-162. PubMed ID: 20525460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Willingness to pay for a quality-adjusted life-year: the individual perspective.
    Bobinac A; Van Exel NJ; Rutten FF; Brouwer WB
    Value Health; 2010 Dec; 13(8):1046-55. PubMed ID: 20825620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Willingness to pay for a QALY.
    Gyrd-Hansen D
    Health Econ; 2003 Dec; 12(12):1049-60. PubMed ID: 14673813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating a constant WTP for a QALY-a mission impossible?
    Sund B; Svensson M
    Eur J Health Econ; 2018 Jul; 19(6):871-880. PubMed ID: 28932914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of studies eliciting willingness-to-pay per quality-adjusted life year: does it justify CE threshold?
    Nimdet K; Chaiyakunapruk N; Vichansavakul K; Ngorsuraches S
    PLoS One; 2015; 10(4):e0122760. PubMed ID: 25855971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Willingness to Pay for Health-Related Quality of Life Gains in Relation to Disease Severity and the Age of Patients.
    Reckers-Droog V; van Exel J; Brouwer W
    Value Health; 2021 Aug; 24(8):1182-1192. PubMed ID: 34372984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of the design of payment scales on the willingness to pay for health gains.
    Soeteman L; van Exel J; Bobinac A
    Eur J Health Econ; 2017 Jul; 18(6):743-760. PubMed ID: 27623946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample restrictions and the elicitation of a constant willingness to pay per quality adjusted life year.
    Nielsen JS; Gyrd-Hansen D; Kjaer T
    Health Econ; 2021 May; 30(5):923-931. PubMed ID: 33569834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Willingness to pay for QALY: perspectives and contexts in Japan.
    Igarashi A; Goto R; Yoneyama-Hirozane M
    J Med Econ; 2019 Oct; 22(10):1041-1046. PubMed ID: 31262236
    [No Abstract]   [Full Text] [Related]  

  • 18. GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation.
    Bobinac A; van Exel NJ; Rutten FF; Brouwer WB
    J Health Econ; 2012 Jan; 31(1):158-68. PubMed ID: 22018622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Handling Protest Responses in Contingent Valuation Surveys.
    Pennington M; Gomes M; Donaldson C
    Med Decis Making; 2017 Aug; 37(6):623-634. PubMed ID: 28199176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Willingness to pay per quality-adjusted life year in a study of knee osteoarthritis.
    Byrne MM; O'malley K; Suarez-Almazor ME
    Med Decis Making; 2005; 25(6):655-66. PubMed ID: 16282216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.